AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03436810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Task-Oriented Circuit Class Training
Description: Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
Study NCT02088242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
Study NCT02088242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
Study NCT02568137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-phone based technology
Study NCT01568788 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza Vaccine
Description: 200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
Study NCT01568788 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine of Pasteur
Description: 200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
Study NCT01568788 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine of GSK
Description: 200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
Study NCT02301611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLPLDC
Description: Autologous tumor lysate, particle-loaded dendritic cell vaccine
Study NCT02301611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00620789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram + CBT-I
Description: * Escitalopram, 10 mg daily for the duration of the study (6 months)~* CBT-I, four biweekly sessions during eight week Treatment phase.
Study NCT00620789 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT-I plus placebo antidepressant medication
Description: * CBT-I, 4 biweekly sessions, eight week Treatment phase.~* Placebo,daily for duration of study(6 months).
Study NCT00620789 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Escitalopram
Description: * Escitalopram, 10 mg daily for the duration of the study (6 months)~* SH, four biweekly sessions during eight week Treatment phase
Study NCT02636842 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole Lauroxil
Description: Intramuscular (IM) injection, single dose
Study NCT04147572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tiotropium inhalation powder type A
Description: Placebo inhalation from inhaler A
Study NCT04147572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spiriva capsule
Description: Placebo inhalation from HandiHaler
Study NCT04147572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Tiotropium inhalation powder type B
Description: Placebo inhalation from inhaler B
Study NCT04147572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Substudy Placebo Tiotropium Easyhaler
Description: Substudy placebo inhalation
Study NCT04147572 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Substudy Placebo Spiriva® via HandiHaler
Description: Substudy placebo inhalation
Study NCT00847639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
Study NCT02917993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
Study NCT02917993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg once daily (QD)
Study NCT05026645 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical interventions performed in acute settings (contaminated environment)
Description: Any clinical intervention performed on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic).
Study NCT05026645 — intervention group
Intervention type: PROCEDURE
Intervention: Protection (clinician and patient)
Description: As interrelated competence of the clinical intervention, any protection procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with.
Study NCT05026645 — intervention group
Intervention type: PROCEDURE
Intervention: Decontamination (clinician and patient)
Description: As interrelated competence of the clinical intervention and protection, any decontamination procedure and capability applied on the patient inflicted by at least one of Chemical, Biological, Radiological, Nuclear, Explosive (CBRNE) weapons in acute settings (from the incident site up to his/her admission to the clean zone of a emergency room or its equivalent (ie.: walking clinic). Concerning the clinician, the protection implied for his/her own safety and for the patient to whom she/he was in closed/contact with. This crucial step is usually expected prior the patient's transfer into a clean zone like the emergency room or its equivalent.
Study NCT03150810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Administered by mouth as a capsule twice daily
Study NCT03150810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: TMZ at various doses administered by mouth as a capsule once daily.
Study NCT04019587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fear of Falling Avoidance Behavior Questionnaire administration
Description: The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
Study NCT03601000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yi-Zhi-An-Shen
Description: Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
Study NCT03601000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules 5g given three times a day for up to 16 weeks.
Study NCT00701376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: liver biopsy
Description: Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
Study NCT03128645 — intervention group
Intervention type: DEVICE
Intervention: Abdominal Corset
Description: The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
Study NCT02801344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal
Description: test drink which contains low amount of amino acids (0.14 g/kg/day)
Study NCT02801344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate
Description: test drink which contains moderate amount of amino acids (0.40 g/kg/day)
Study NCT02801344 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High
Description: test drink which contains high amount of amino acids (1.03 g/kg/day)
Study NCT02801344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled-diet
Description: the diet containing 0.8 g protein /kg/day
Study NCT02745769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02745769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally
Study NCT02745769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT01359410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh reinforced staple line (SEAMGUARD)
Description: Reinforce the pancreatic transaction with SEAMGUARD®
Study NCT01359410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled without mesh reinforcement (PER-STRIPS DRY)
Description: Stapled without mesh reinforcement (PERI-STRIPS DRY®)
Study NCT00994279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Yoga sessions
Study NCT00994279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational Wellness Group
Study NCT03923387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MynxGrip
Description: Vascular Closure
Study NCT03923387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Manual compression is a commonly used method to achieve hemostasis of femoral artery
Study NCT00693030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)
Description: comparison of multiple drug eluting stents
Study NCT00693030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)
Description: comparison of multiple drug eluting coronary stents
Study NCT00693030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)
Description: comparison of multiple drug eluting coronary stents
Study NCT00693030 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)
Description: comparison of DES in overlap vs BMS in overlap
Study NCT03445481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medacta femoral prosthesis
Description: patients' treatment with a new implant prosthesis
Study NCT03936322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimally invasive fetoscopic repair of MMC
Description: Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
Study NCT00859014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Mononuclear Cells
Description: Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
Study NCT00162942 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adacolumn
Description: Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9).
Study NCT00162942 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham, ten apheresis sessions within 9 weeks
Study NCT02179645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 27864
Study NCT02179645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study NCT02179645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02723656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Referral NYS Quitline
Description: Care coordinator will make an online referral to the NYS Quitline.
Study NCT02723656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco cessation counseling and coordination of cessation medications
Description: Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
Study NCT03496961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yan Nian Jiu Zhuan Fa
Description: Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
Study NCT01554228 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observational study to examine changes in cognition following bariatric surgery after one year.
Study NCT02788474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Study NCT02788474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03496961 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yan Nian Jiu Zhuan Fa
Description: Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
Study NCT04502927 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Passive extension mobilization of the hand and wrist joints
Description: The physiotherapist will proceed with the passive mobilization of the spastic hand of the stroke patient or the dominant hand for healthy volunteers.~Two mobilizations will be performed for each participant, i.e. one for each type of medial or lateral grip. The order of mobilization will be determined by randomization.
Study NCT02888795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic dextrose prolotherapy
Description: five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
Study NCT02931162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion
Description: Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Study NCT02931162 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham herb-partitioned moxibustion
Description: Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
Study NCT00843362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal pessary
Description: 10 mg controlled-release dinoprostone pessary applied for 24 hours
Study NCT00843362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone vaginal gel
Description: 2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
Study NCT04700319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19/CD20 CAR-T cell infusion
Description: CD19/CD20 CAR-T,Infusion,iv,0.2×10\^6-5×10\^6γδT /kg,once
Study NCT01575145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline facilitation intervention
Description: brief quitline facilitation intervention
Study NCT01575145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief stop-smoking intervention
Description: brief review of tips to help maintain smoking abstinence, using brochure
Study NCT00602901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA-SM
Description: High-velocity low amplitude spinal manipulation (HVLA-SM)
Study NCT00602901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LVVA-SM
Description: Low-velocity variable amplitude spinal manipulation (LVVA-SM)
Study NCT00602901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
Study NCT01444976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: patients will receive only topical anesthesia with 1% lidocaine
Study NCT01444976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hypnosis
Description: Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
Study NCT01444976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
Study NCT04682574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: mega dose is given to the selected critically ill patients
Study NCT02758678 — intervention group
Intervention type: BIOLOGICAL
Intervention: A single 2 ml heparinised peripheral blood sample
Description: A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
Study NCT02609555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEM perineal rectopexy
Description: perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
Study NCT00498537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: spironolactone
Study NCT02433327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEWS - trigger tool
Description: PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
Study NCT02433327 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RM - trigger tool
Description: RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
Study NCT04428775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZT-OP1a (cromolyn)
Description: 1. Mast cell stabilizer~2. Neuroinflammatory microglial modulator~3. anti-inflammatory
Study NCT02245204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid
Description: Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
Study NCT00222729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV q 21 days following pemetrexed
Study NCT04205994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 MG
Description: Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in randomized, double-blind, counterbalanced fashion with a placebo.
Study NCT01783457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.